OncoMatch/Clinical Trials/NCT04581512
Study to Evaluate the Safety and Tolerability of EP0042
Official title: A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Is NCT04581512 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments including EP0042 and Venetoclax for acute myeloid leukemia.
Treatment: EP0042 · Venetoclax · Azacitidine (AZA) — A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: FLT3 wild-type
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
creatinine clearance < 50 ml/min
Liver function
Exact limits: see the full eligibility criteria on this page.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04581512 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require FLT3?
Yes, FLT3 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify